VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

3 Customer Reviews

  • J Invest Dermatol, 2018, 138(6):1380-1390. VX-702 purchased from Selleck.

    Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

  •  Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell M2fQemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkP4TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlAyPTR|IN88US=> M36xTHNCVkeHUh?=
human NCI-H720 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPIR|VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1? NUj6XFlEW0GQR1XS
JVM-2 cell NFjPOpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrkTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFg{KM7:TR?= NVz2PY1sW0GQR1XS
human NCI-H69 cell NXTlOnp6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6QTRzIN88US=> MWXTRW5ITVJ?
human BV-173 cell M{\S[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPiT3FMUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFzM{i2JO69VQ>? NFjOV2VUSU6JRWK=
human KU812 cell NVeyU4gxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGixWYRKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjR6ODFOwG0> NXHTTnRPW0GQR1XS
human DU-145 cell NH7tR|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPETY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=> NYrl[3BoW0GQR1XS
KARPAS-45 cell MlzrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlLPTY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2OEK2JO69VQ>? MnvTV2FPT0WU
human AGS cell MnXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXMenYyUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjVzIN88US=> NF7wdZhUSU6JRWK=
human MOLT-13 cell M3vxfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDGfWRKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUixJO69VQ>? MlnqV2FPT0WU
human NCI-H209 cell M1mw[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWrveFdvUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUe1PEDPxE1? Mn2zV2FPT0WU
human CTV-1 cell NEPqbFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNVXi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPFM5QSEQvF2= MVLTRW5ITVJ?
LU-139 cell NF3tbnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4rpVWlvcGmkaYTpc44hd2ZiaIXtZY4hVFVvMUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQTR|NTFOwG0> MnPiV2FPT0WU
ML-2 cell Mo\JS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= NH\TTHJUSU6JRWK=
human K5 cell M3rheGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnT1TY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK5NVch|ryP NVrBc4duW0GQR1XS
human SBC-1 cell NWjQNGs1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUC3UGt6UW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> NGjJeoZUSU6JRWK=
human COR-L88 cell NHHzV|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PDhizszN MnS5V2FPT0WU
human KY821 cell MnfiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKGi3bXHuJGt[QDJzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPVYxOyEQvF2= MVnTRW5ITVJ?
human HCC2218 cell M2jEN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIX4[YNKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>? M4\PbXNCVkeHUh?=
human ECC10 cell NWT3eJc{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGVESzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OVM5QSEQvF2= NVHF[YFQW0GQR1XS
human EW-3 cell NU[1NnBPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXOb5NKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY3PjFzIN88US=> NFvTcXpUSU6JRWK=
human EW-18 cell NID1S5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLjWIV6UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzR4N{mg{txO MmfEV2FPT0WU
human UACC-257 cell M2HJZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVzJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODN{NjFOwG0> MVrTRW5ITVJ?
human G-361 cell NILvTI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\hTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN NFr4TJpUSU6JRWK=
human HMV-II cell NYX1dI9lT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4T1fWlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PzF6NDFOwG0> M3LVUXNCVkeHUh?=
human DEL cell NUjlOo9qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLITY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKwO|A1KM7:TR?= M12yR3NCVkeHUh?=
human IGROV-1 cell NInWWVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> M3nEcHNCVkeHUh?=
human SK-OV-3 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYyPjl5IN88US=> NFraNGVUSU6JRWK=
human LAMA-84 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPReVVsUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55MUK4OEDPxE1? Mle4V2FPT0WU
human NCI-H510A cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXrjSHhFUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyOVI3KM7:TR?= M3jnXHNCVkeHUh?=
human CP66-MEL cell NInaR|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvqNIwxUW6qaXLpeIlwdiCxZjDoeY1idiCFUE[2MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUO1OVkh|ryP NEnlS2NUSU6JRWK=
human HAL-01 cell MmnvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7CVoxKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO MX7TRW5ITVJ?
human RS4-11 cell  NYPZeYE{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLBUZpOUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjdyNUezJO69VQ>? NH;QU|lUSU6JRWK=
human RPMI-8226 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVfCSm5pUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkiyN|c3KM7:TR?= NVL0OYpKW0GQR1XS
human NCI-H82 cell NFHSNmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXj3Z|g4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56OUOwOUDPxE1? MlvXV2FPT0WU
human NY cells MnzrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoXWTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMke2N|ch|ryP M4TXZnNCVkeHUh?=
human MDA-MB-361 cell NIrBSWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFfaOGNKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkSzNVU5KM7:TR?= M4f6XnNCVkeHUh?=
human MOLT-4 cell Mm\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVy4b2UxUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? MXvTRW5ITVJ?
human DU-4475 cell MmPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWDkdIFDUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yNUW2OUDPxE1? NVrsOpJKW0GQR1XS
human ESS-1 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3m2[2lvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6OTd7IN88US=> MmrHV2FPT0WU
human NCI-H1299 cell M1PXdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{H5cmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? MlrWV2FPT0WU
human COLO-684 cell M3vCPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rBUWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV6MU[1JO69VQ>? Mn\oV2FPT0WU
human MV-4-11 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEi4RXhKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjdzMUm5JO69VQ>? Mn7XV2FPT0WU
human D-542MG cell NVr4SmpOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVrwcWtCUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|OUK3NkDPxE1? NXjxc2VGW0GQR1XS
human A4-Fuk cell NFTwenJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnruTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{PjZ{IN88US=> MlnaV2FPT0WU
human HL-60 cell NVLpV|FMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYHufWFIUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO NILPO4FUSU6JRWK=
human NCI-H526 cell NGXSfJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;Kc4xHUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwNUm4NFEh|ryP M2fW[HNCVkeHUh?=
human L-363 cell Mn3rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLvSXpKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{44QTJ3MjFOwG0> M{DiWXNCVkeHUh?=
human A388 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkiwN|g1KM7:TR?= MXfTRW5ITVJ?
human MS-1 NUfBZlRzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlOzTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64N|Q3PSEQvF2= NFfzOZhUSU6JRWK=
human JAR cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUjWZ3Q5UW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg1QTJ|IN88US=> NFTVbXNUSU6JRWK=
human TI-73 cell NUjCbYZST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml\HTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFYzOiEQvF2= Mn3XV2FPT0WU
human CTB-1 cell Mm\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmK2TY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN MkDNV2FPT0WU
human SK-NEP-1 cell MoGxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jUNWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5|MEO4JO69VQ>? MoDjV2FPT0WU
human HT-29 cell NGrhd45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYnvRmlVUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{NjlzMUGg{txO NELtWpdUSU6JRWK=
human NCI-H1092 cell NI\oPXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvEfFg3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExQTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND6zNVgh|ryP NVH0[JZKW0GQR1XS
human KMOE-2 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7aTY5pcWKrdHnvckBw\iCqdX3hckBMVU:HLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE43OTd6IN88US=> NWHLe2JNW0GQR1XS
human EM-2 cell NFLDemdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4r2SmlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlI5PDFizszN NVX4OYtlW0GQR1XS
human RT-112 cell M4Tzbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF6xbpJKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjN7OESg{txO MVTTRW5ITVJ?
human DB cell M{nVOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1? MV3TRW5ITVJ?
human NCI-H1770 cell NG\XfXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoO4TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? MkTyV2FPT0WU
human CAL-54 cell MmO4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfrVYJKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> M1vybHNCVkeHUh?=
human NB14 cell M3;YPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNz62N|k2KM7:TR?= NEDi[ZJUSU6JRWK=
human RPMI-7951 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIXCdm9KdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP NFH6VXhUSU6JRWK=
human T47D cell NWLt[WpxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYjmXlNRUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOjJ2MzFOwG0> MUHTRW5ITVJ?
human A549 cell MmnLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moe2TY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlgyOSEQvF2= M2\RTHNCVkeHUh?=
human A2780 cell NH;QOnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjLTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlgzOjVizszN M2fKVHNCVkeHUh?=
human SK-MEL-24 cell NVXySWE3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1HQbGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? M3;3VXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID